Bifogade filer
PDF
Kurs
+3,77%
Likviditet
0,09 MSEK
Kalender
| Tid* | ||
| 2025-05-20 | N/A | Årsstämma |
| 2025-05-20 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-25 | 08:00 | Bokslutskommuniké 2024 |
| 2024-12-17 | - | Extra Bolagsstämma 2024 |
| 2024-11-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-29 | - | Extra Bolagsstämma 2022 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | Split SYNT 1:10 |
| 2021-05-12 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-02 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2020-07-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-05 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-30 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2019-04-29 | - | Årsstämma |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2018-04-25 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2017-04-25 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-27 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2016-04-26 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-10-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-13 | - | Årsstämma |
| 2015-04-13 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2015-02-13 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-26 | - | Extra Bolagsstämma 2014 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
SyntheticMR announced today that its quantitative imaging software solution, SyMRI 12, has received regulatory approval from the Taiwan Food and Drug Administration (TFDA). This milestone enables the sale and distribution of SyMRI 12 in the Taiwanese market, paving the way for regional expansion.
[image]
"This approval of SyMRI 12 opens new opportunities for us to expand our market presence in Taiwan and the Southeast Asia region. We are excited to offer SyMRI 12 to radiologists in this market, providing them with new insights and enhancing their practice through our unique technology and objective, quantitative data," says Ulrik Harrysson, CEO at SyntheticMR.
The approval in Taiwan represents a significant step in SyntheticMR's global expansion strategy. By entering the Taiwanese market, the company aims to support local healthcare providers with cutting-edge imaging technology, ultimately improving patient care outcomes.
This regulatory approval signifies a strong potential for growth and increased market presence in the Asia-Pacific region.
About SyMRI: SyMRI provides multiple contrast-weighted images and quantitative information about the patient in a single fast scan, enabling users to speed up their imaging workflow and add objective decision support to their practice.
About SyntheticMR: SyntheticMR develops innovative imaging solutions that provide richer and more comprehensive data to radiologists. Their technology is designed to enhance clinical decision-making, streamline workflows, and improve patient outcomes.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.